79 related articles for article (PubMed ID: 9135002)
1. Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint?
Wang Y; Perrault AR; Iliakis G
Cancer Res; 1997 May; 57(9):1654-9. PubMed ID: 9135002
[TBL] [Abstract][Full Text] [Related]
2. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
3. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
Sané AT; Bertrand R
Cancer Res; 1999 Aug; 59(15):3565-9. PubMed ID: 10446962
[TBL] [Abstract][Full Text] [Related]
4. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
6. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
8. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
10. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
12. The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.
Ramirez-Santoyo R; Lopez-Swiderski A; Avalos-Diaz E; Herrera-Esparza R
Rev Rhum Engl Ed; 1998 Mar; 65(3):165-72. PubMed ID: 9574473
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity.
Beidler DR; Cheng YC
Mol Pharmacol; 1995 May; 47(5):907-14. PubMed ID: 7538195
[TBL] [Abstract][Full Text] [Related]
14. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
15. Evidence for activities inhibiting in trans initiation of DNA replication in extract prepared from irradiated cells.
Wang Y; Huq MS; Iliakis G
Radiat Res; 1996 Apr; 145(4):408-18. PubMed ID: 8600501
[TBL] [Abstract][Full Text] [Related]
16. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL modulates apoptosis induced by anticancer drugs and delays DEVDase and DNA fragmentation-promoting activities.
Schmitt E; Cimoli G; Steyaert A; Bertrand R
Exp Cell Res; 1998 Apr; 240(1):107-21. PubMed ID: 9570926
[TBL] [Abstract][Full Text] [Related]
18. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
19. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
Bendetz-Nezer S; Gazit A; Priel E
Mol Pharmacol; 2004 Sep; 66(3):627-34. PubMed ID: 15322255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
